Rearrangements of the BCL6 gene have been observed in 28.6-35.5% of Diffuse Large B-Cell Lymphoma (DLBCL) and in 6.4-14.3% of Follicular Lymphoma (FL)1.
This translocation results in the dysregulation of BCL6 and may involve the IGH, IGK and IGL genes, although other non-Ig partner genes have also been identified2,3. BCL6 encodes a 95kD nuclear phosphoprotein belonging to the pox virus zinc finger (POZ)/zinc finger (ZF) family of transcription factors4. BCL6 functions as a transcriptional repressor and plays an important regulatory role in lymphoid cell development and function. In the B-cell lineage, the BCL6 protein is expressed only in germinal centre B cells5. Translocations involving band 3q27.3 affect a 4kb major breakpoint region of BCL6 in the first non-coding exon and 5' region of the first intron, and are common in diffuse large B-cell lymphomas. Recently, an alternative breakpoint cluster region located between 245 and 285kb 5' of BCL6 was identified in Non-Hodgkin Lymphoma (NHL) and may be preferentially associated with follicular lymphoma6.
1. Ohno H et al., Leuk Lymphoma 1997;27: 53-63
2. Ueda C et al., Leuk Lymphoma 2002;43: 1375-81
3. Akasaka H et al., Cancer Res 2000; 60: 2335-41
4. Chang CC et al., PNAS 1996;93: 6947-52
5. Cattoretti G et al., Blood 1995;85:45-53
6. Bosga-Bouwer AG et al., Genes Chrom Cancer 2005;44: 301-304
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.